Increased Fibroblast Growth Factor 21 in Nonalcoholic Fatty Liver Disease

被引：0
|
作者：
Dushay, Jody
Chui, Patricia
Gopalakrishnan, Gosala S.
Varelarey, Marta
Crawley, Meghan
Fisher, Ffolliott M.
Badman, Michael K.
Martinez-Chantar, Maria L.
Maratos-Flier, Eleftheria
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A414 / A414
页数：1
相关论文
共 50 条
  • [1] Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
    Dushay, Jody
    Chui, Patricia C.
    Gopalakrishnan, Gosala S.
    Varela-Rey, Marta
    Crawley, Meghan
    Fisher, Ffolliott M.
    Badman, Michael K.
    Martinez-Chantar, Maria L.
    Maratos-Flier, Eleftheria
    GASTROENTEROLOGY, 2010, 139 (02) : 456 - 463
  • [2] Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
    Li, Huating
    Fang, Qichen
    Gao, Fei
    Fan, Jia
    Zhou, Jian
    Wang, Xiaoying
    Zhang, Huizhen
    Pan, Xiaoping
    Bao, Yuqian
    Xiang, Kunsan
    Xu, Aimin
    Jia, Weiping
    JOURNAL OF HEPATOLOGY, 2010, 53 (05) : 934 - 940
  • [3] Fibroblast Growth Factor 21 Levels Are Increased in Nonalcoholic Fatty Liver Disease Patients and Correlated with Hepatic Triglyceride
    Li, Huating
    Fang, Qichen
    Fan, Jia
    Zhou, Jian
    Wang, Xiaoying
    Gao, Fei
    Zhang, Huizhen
    Pan, Xiaoping
    Bao, Yuqian
    Xiang, Kunsan
    Xu, Aimin
    Jia, Weiping
    DIABETES, 2010, 59 : A409 - A410
  • [4] Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
    Raptis, Dimitrios
    Mantzoros, Christos S.
    Polyzos, Stergios A.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 77 - 96
  • [5] Is Trimming the Fat Enough? Fibroblast Growth Factor 21 as An Emerging Treatment for Nonalcoholic Fatty Liver Disease
    Dushay, Jody
    Lai, Michelle
    HEPATOLOGY, 2019, 70 (05) : 1860 - 1862
  • [6] The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease
    Chrysavgis, Lampros
    Giannakodimos, Ilias
    Chatzigeorgiou, Antonios
    Tziomalos, Konstantinos
    Papatheodoridis, George
    Cholongitas, Evangelos
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (09) : 835 - 849
  • [7] Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
    Ritchie, Michael
    Hanouneh, Ibrahim A.
    Noureddin, Mazen
    Rolph, Timothy
    Alkhouri, Naim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 197 - 204
  • [8] Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events
    Wu, Liang
    Qian, Lingling
    Zhang, Lei
    Zhang, Jing
    Zhou, Jia
    Li, Yuehua
    Hou, Xuhong
    Fang, Qichen
    Li, Huating
    Jia, Weiping
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (11):
  • [9] Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
    Guangyu Wu
    Huating Li
    Qichen Fang
    Jing Zhang
    Mingliang Zhang
    Lei Zhang
    Liang Wu
    Xuhong Hou
    Junxi Lu
    Yuqian Bao
    Weiping Jia
    Scientific Reports, 7
  • [10] Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
    Wu, Guangyu
    Li, Huating
    Fang, Qichen
    Zhang, Jing
    Zhang, Mingliang
    Zhang, Lei
    Wu, Liang
    Hou, Xuhong
    Lu, Junxi
    Bao, Yuqian
    Jia, Weiping
    SCIENTIFIC REPORTS, 2017, 7
12345